Thomas E Jenkins
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$6.3MFederal grants as PI9 awards
6Patents grantedLatest May 3, 2022
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $6.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 25, 2019 | NIH | SBIR Phase II Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | $990K | ELYSIUM THERAPEUTICS, INC. |
| Jul 11, 2018 | NIH | SBIR Phase II Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | $985K | ELYSIUM THERAPEUTICS, INC. |
| Jun 11, 2018 | NIH | SBIR Phase I Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | $50K | ELYSIUM THERAPEUTICS, INC. |
| Feb 22, 2018 | NIH | SBIR Phase I Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods | $225K | ELYSIUM THERAPEUTICS, INC. |
| Apr 17, 2017 | NIH | SBIR Phase II Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids | $987K | ELYSIUM THERAPEUTICS, INC. |
| Apr 21, 2016 | NIH | SBIR Phase II Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs | $355K | ELYSIUM THERAPEUTICS, INC. |
| Jun 10, 2015 | NIH | SBIR Phase II Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs | $5K | ELYSIUM THERAPEUTICS, INC. |
| Apr 22, 2015 | NIH | SBIR Phase II Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs | $1.1M | ELYSIUM THERAPEUTICS, INC. |
| Feb 27, 2015 | NIH | SBIR Phase II Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance | $1.5M | ELYSIUM THERAPEUTICS, INC. |
7 patents as inventor
- US 10251878ELYSIUM THERAPEUTICS, INC.Apr 9, 2019
- US 10335406ELYSIUM THERAPEUTICS, INC.Jul 2, 2019
- US 11129825ELYSIUM THERAPEUTICS, INC.Sep 28, 2021
- US 11154549ELYSIUM THERAPEUTICS, INC.Oct 26, 2021
- US 11197933ELYSIUM THERAPEUTICS, INC.Dec 14, 2021
- US 11318132ELYSIUM THERAPEUTICS, INC.May 3, 2022
- US ELYSIUM THERAPEUTICS, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#169
Awards as PI#151
Patents#15
Companies
- ELYSIUM THERAPEUTICS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.